Comparison · NCT02940860-f36308dc
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8. Trial comparisons, record NCT02940860-f36308dc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02940860-f36308dc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.299 | 0.272 | 0.328 | wilson | |
| Risk in group 2 | 0.261 | 0.225 | 0.301 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0381 | -0.0101 | 0.0844 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.15 | 0.964 | 1.36 | log | |
| Odds ratio, group 1 over group 2 | 1.21 | 0.952 | 1.53 | log | |
| Number needed to treat, for one more participant with the outcome on Iron Isomaltoside/Ferric Derisomaltose than on Iron Sucrose | 26.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | 307 | 1,027 | OG000 |
| Group 2 | Iron Sucrose | Iron sucrose, administered IV | 133 | 510 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8
- Description
- Efficacy~Results show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8.
- Time frame
- Week 1 to week 8
- Population
- ITT. All randomised subjects.
Source ClinicalTrials.gov
Trial
- Title
- Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
- NCT number
- NCT02940860
- Phases
- PHASE3
- Conditions
- Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
- Interventions
- Iron isomaltoside/ferric derisomaltose, Iron sucrose
- Lead sponsor
- Pharmacosmos A/S
- Results first posted
- 2020-03-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02940860?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02940860-f36308dc